Subclinical TRAPS treated with canakinumab
Tumor necrosis factor receptor–associated periodic syndrome (TRAPS) is a rare autoinflammatory disease characterized by recurrent episodes of fever and systemic inflammation. We describe the case of a 19-year-old patient who was referred to our attention with frequent subclinical TRAPS episodes char...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2021-08-01
|
| Series: | Reumatismo |
| Subjects: | |
| Online Access: | https://reumatismo.org/index.php/reuma/article/view/1406 |
| _version_ | 1818217674320117760 |
|---|---|
| author | M. Amatruda N.S. Carucci C. Fede G. Conti |
| author_facet | M. Amatruda N.S. Carucci C. Fede G. Conti |
| author_sort | M. Amatruda |
| collection | DOAJ |
| description | Tumor necrosis factor receptor–associated periodic syndrome (TRAPS) is a rare autoinflammatory disease characterized by recurrent episodes of fever and systemic inflammation. We describe the case of a 19-year-old patient who was referred to our attention with frequent subclinical TRAPS episodes characterized by mild arthralgias and crampy abdominal pain, without fever. Inflammatory markers, including serum amyloid A which increases the risk of long-term amyloidosis, were persistently high also when the patient was in good general conditions. Therapy with human anti-interleukin 1β monoclonal antibody, canakinumab, led to disease control and normalization of the inflammatory markers, which are currently still normal. This clinical case supports the need to treat also subclinical TRAPS. In this respect, canakinumab is effective and reduces the risk of developing amyloidosis. |
| first_indexed | 2024-12-12T07:11:37Z |
| format | Article |
| id | doaj.art-bb60fb069ea445b99c5e8e720f1beafa |
| institution | Directory Open Access Journal |
| issn | 0048-7449 2240-2683 |
| language | English |
| last_indexed | 2024-12-12T07:11:37Z |
| publishDate | 2021-08-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Reumatismo |
| spelling | doaj.art-bb60fb069ea445b99c5e8e720f1beafa2022-12-22T00:33:37ZengPAGEPress PublicationsReumatismo0048-74492240-26832021-08-0173210.4081/reumatismo.2021.1406Subclinical TRAPS treated with canakinumabM. Amatruda0N.S. Carucci1C. Fede2G. Conti3Pediatric Nephrology and Rheumatology Unit with Dialysis, Department of Human Pathology in Adulthood and Childhood “G. Barresi”; AOU Policlinic “G. Martino”, Messina UniversityPediatric Nephrology and Rheumatology Unit with Dialysis, Department of Human Pathology in Adulthood and Childhood “G. Barresi”; AOU Policlinic “G. Martino”, Messina UniversityPediatric Nephrology and Rheumatology Unit with Dialysis, Department of Human Pathology in Adulthood and Childhood “G. Barresi”; AOU Policlinic “G. Martino”, Messina UniversityPediatric Nephrology and Rheumatology Unit with Dialysis, Department of Human Pathology in Adulthood and Childhood “G. Barresi”; AOU Policlinic “G. Martino”, Messina UniversityTumor necrosis factor receptor–associated periodic syndrome (TRAPS) is a rare autoinflammatory disease characterized by recurrent episodes of fever and systemic inflammation. We describe the case of a 19-year-old patient who was referred to our attention with frequent subclinical TRAPS episodes characterized by mild arthralgias and crampy abdominal pain, without fever. Inflammatory markers, including serum amyloid A which increases the risk of long-term amyloidosis, were persistently high also when the patient was in good general conditions. Therapy with human anti-interleukin 1β monoclonal antibody, canakinumab, led to disease control and normalization of the inflammatory markers, which are currently still normal. This clinical case supports the need to treat also subclinical TRAPS. In this respect, canakinumab is effective and reduces the risk of developing amyloidosis.https://reumatismo.org/index.php/reuma/article/view/1406TRAPSIL-1canakinumabAA amyloidosis. |
| spellingShingle | M. Amatruda N.S. Carucci C. Fede G. Conti Subclinical TRAPS treated with canakinumab Reumatismo TRAPS IL-1 canakinumab AA amyloidosis. |
| title | Subclinical TRAPS treated with canakinumab |
| title_full | Subclinical TRAPS treated with canakinumab |
| title_fullStr | Subclinical TRAPS treated with canakinumab |
| title_full_unstemmed | Subclinical TRAPS treated with canakinumab |
| title_short | Subclinical TRAPS treated with canakinumab |
| title_sort | subclinical traps treated with canakinumab |
| topic | TRAPS IL-1 canakinumab AA amyloidosis. |
| url | https://reumatismo.org/index.php/reuma/article/view/1406 |
| work_keys_str_mv | AT mamatruda subclinicaltrapstreatedwithcanakinumab AT nscarucci subclinicaltrapstreatedwithcanakinumab AT cfede subclinicaltrapstreatedwithcanakinumab AT gconti subclinicaltrapstreatedwithcanakinumab |